利妥昔单抗维持治疗期间血浆浓度与抗中性粒细胞胞质抗体相关性血管炎重大复发风险的关联
本研究为MAINRITSAN 2试验的辅助研究,纳入135例抗中性粒细胞胞质抗体相关性血管炎患者,随机接受固定方案或个体化方案利妥昔单抗输注。固定方案组第3个月暴露不足(<4 μg/ml)频率低于个体化组(2.0% vs 18.0%;P=0.02)。第3个月利妥昔单抗血浆浓度<4 μg/ml是第28个月重大复发的独立危险因素(OR 6.56 [95%CI 1.26-34.09];P=0.025)。作者认为药物监测可能有助于个体化维持期利妥昔单抗给药方案。
要点
- 固定方案组第3个月暴露不足(<4 μg/ml)频率低于个体化组(2.0% vs 18.0%;P=0.02)。
- 第3个月利妥昔单抗血浆浓度<4 μg/ml是第28个月重大复发的独立危险因素(OR 6.56 [95%CI 1.26-34.09];P=0.025)。
- 敏感性生存分析中,第3个月浓度<4 μg/ml为重大复发(HR 4.81 [95%CI 1.56-14.82];P=0.006)和复发(HR 2.70 [95%CI 1.02-7.15];P=0.046)的独立危险因素。
核心结论
- 作者认为药物监测可能有助于在维持期内个体化利妥昔单抗给药方案。
研究设计与样本
- MAINRITSAN 2试验(ClinicalTrials.gov标识符:NCT01731561)的辅助研究,135例患者随机接受500 mg固定方案利妥昔单抗输注或个体化方案。
- 评估第3个月利妥昔单抗血浆浓度;对53份DNA样本进行88个推定药代动力学/药效动力学候选基因的单核苷酸多态性基因分型。
- 采用加性和隐性遗传模型的逻辑线性回归探讨药代动力学/药效动力学结局与遗传变异的关系。
主要发现
- 固定方案组暴露不足(<4 μg/ml)患者频率为2.0%,个体化输注组为18.0%(P=0.02)。
- 第3个月利妥昔单抗血浆浓度<4 μg/ml是第28个月重大复发的独立危险因素(OR 6.56 [95%CI 1.26-34.09];P=0.025)。
- 敏感性生存分析中,第3个月浓度<4 μg/ml是重大复发的独立危险因素(HR 4.81 [95%CI 1.56-14.82];P=0.006),也是复发的独立危险因素(HR 2.70 [95%CI 1.02-7.15];P=0.046)。
- STAT4 rs2278940和PRKCA rs8076312与第3个月浓度显著相关,但与第28个月重大复发发生无关。
关键数值与推荐
- 暴露不足定义为利妥昔单抗血浆浓度<4 μg/ml。
- 固定方案组第3个月暴露不足频率2.0% vs 个体化输注组18.0%(P=0.02)。
- 第3个月浓度<4 μg/ml vs ≥4 μg/ml:第28个月重大复发OR 6.56(95%CI 1.26-34.09;P=0.025)。
- 第3个月浓度<4 μg/ml vs ≥4 μg/ml:重大复发HR 4.81(95%CI 1.56-14.82;P=0.006),复发HR 2.70(95%CI 1.02-7.15;P=0.046)。
临床怎么用
- 作者认为药物监测可能有助于在维持期内个体化利妥昔单抗给药方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interindividual variability in response to rituximab remains unexplored in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rituximab pharmacokinetics (PK) and pharmacodynamics (PD) as well as genetic polymorphisms could contribute to variability. This ancillary study of the MAINRITSAN 2 trial aimed to explore the relationship between rituximab plasma concentration, genetic polymorphisms in PK/PD candidate genes, and clinical outcomes. METHODS: Patients included in the MAINRITSAN2 trial (ClinicalTrials.gov identifier: NCT01731561) were randomized to receive a 500-mg fixed-schedule rituximab infusion or an individually tailored regimen. Rituximab plasma concentrations at month 3 (CM3) were assessed. DNA samples (n = 53) were genotyped for single-nucleotide polymorphisms within 88 putative PK/PD candidate genes. The relationship between PK/PD outcomes and genetic variants was investigated using logistic linear regression in additive and recessive genetic models. RESULTS: One hundred and thirty-five patients were included. The frequency of underexposed patients (<4 μg/ml) in the fixed-schedule group was statistically lower compared to that in the tailored-infusion group (2.0% versus 18.0%; P = 0.02, respectively). Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml) was an independent risk factor for major relapse (odds ratio 6.56 [95% confidence interval (95% CI) 1.26-34.09]; P = 0.025) at month 28 (M28). A sensitivity survival analysis also identified CM3 <4 μg/ml as an independent risk factor for major relapse (hazard ratio [HR] 4.81 [95% CI 1.56-14.82]; P = 0.006) and relapse (HR 2.70 [95% CI 1.02-7.15]; P = 0.046). STAT4 rs2278940 and PRKCA rs8076312 were significantly associated with CM3 but not with major relapse onset at M28. CONCLUSION: These results suggest that drug monitoring could be useful to individualize the schedule of rituximab administration within the maintenance phase.
引用
- Khoudour N, Delestre F, Jabot-Hanin F, et al. Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance Therapy. Arthritis Rheumatol. 2023. PMID: 37134130. doi:10.1002/art.42556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。